Effects of intranasal steroids on continuous positive airway pressure compliance among patients with obstructive sleep apnea
| Autor: | Rutti Chumthong, Prasit Mahakit, Charnsiri Segsarnviriya |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_treatment Fluticasone propionate law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Surveys and Questionnaires Nose Diseases medicine Humans Continuous positive airway pressure Prospective Studies Administration Intranasal Sleep Apnea Obstructive rhinorrhea Continuous Positive Airway Pressure business.industry Nasal Sprays Middle Aged medicine.disease respiratory tract diseases Obstructive sleep apnea Clinical trial Androstadienes 030228 respiratory system Otorhinolaryngology Nasal spray Anesthesia Patient Compliance Nasal administration Female Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Sleepbreathing = SchlafAtmung. 25(3) |
| ISSN: | 1522-1709 |
| Popis: | Continuous positive airway pressure (CPAP) in the treatment of obstructive sleep apnea can produce troublesome nasal symptoms, especially congestion, which may affect the continuity of using CPAP. Intranasal steroids are often prescribed to reduce these side effects, although few recent studies exist supporting the benefits of this treatment for CPAP-induced nasal side effects. Eighty-three patients with OSA were enrolled in a prospective, randomized controlled study. All patients received CPAP treatment and were divided in two groups. The study group was prescribed fluticasone furoate nasal spray 55 μg, and the compliance to CPAP for patients in both groups was recorded by device memory card. Total nasal symptom score was assessed using a questionnaire by direct interview, with follow-up performed at 30 and 90 days after treatment. Compliance to CPAP increased in both groups with significantly greater compliance in the intranasal steroid group compared to the control group without intranasal steroid (P value = 0.002, 0.001, and 0.020, respectively) after 90 days of treatment. No difference in nasal symptoms was found between the groups after 30 days of treatment. However, adding an intranasal steroid resulted in decreased rhinorrhea and congestion symptoms (P value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink